The trial follows on from the Phase II LixiPark trial (NCT03439943) that saw Parkinson’s patients dosed with Sanofi’s GLP-1RA Lyxumia (lixisenatide), which appeared to slow disease progression ...
The trial follows on from the Phase II LixiPark trial (NCT03439943) that saw Parkinson’s patients dosed with Sanofi’s GLP-1RA Lyxumia (lixisenatide), which appeared to slow disease progression when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback